COVID-19: Putting safety measures into practice

Article

Arshad Khanani, MD, offers insight on the safety measures he and staff have implemented at the Sierra Eye Associates multi-specialty practice in Reno, Nevada, to ensure proper caution for the sake of both physicians and patients during the coronavirus epidemic.

 

See more coronavirus coverage

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Related Content
A syringe and containers of liquid in front of the European Medicines Agency logo. Concept image for aflibercept Eylea EMA approval. Image credit: ©SoniaBonet – stock.adobe.com

Bayer submits EMA application for aflibercept 8mg third indication, retinal vein occlusion

Hattie Hayes
April 9th 2025
Article

In the European Union and the United Kingdom, aflibercept 8mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular oedema

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
An image of two older adults on a bench. Concept image for giant cell arteritis and vision loss from sudden ocular change in vasculitis. Image credit: ©C Coetzee/peopleimages.com – stock.adobe.com

European Commission expands upadacitinib (Rinvoq) indication to include giant cell arteritis

Hattie Hayes
April 8th 2025
Article

Patients with GCA, an autoimmune disease, are at risk for sudden vision loss which can be permanent

A photo of the United States Food and Drug Administration FDA headquarters. Concept image for FDA ophthalmic presbyopia treatment application submission. Image credit: ©Tada Images – stock.adobe.com

Tenpoint Therapeutics submits US FDA New Drug Application for presbyopia treatment BRIMOCHOL PF

Jordana Joy
April 8th 2025
Article

Following Phase 3 pivotal trial BRIO-II, Tenpoint Therapeutics said they hope to launch BRIMOCHOL PF in 2026

A dermatologist examines a child's arm for evidence of atopic dermatitits. Concept image for link between AD and paediatric uveitis. Image credit: ©Kate – stock.adobe.com

Paediatric patients with early-onset atopic dermatitis show higher uveitis risk

Lynda Charters
April 8th 2025
Article

The study findings support the need to consider ophthalmologic monitoring in children with early-onset atopic dermatitis

A map of Europe with a digital overlay. Concept image for European EU commercialisation and CE mark. Image credit: ©garrykillian – stock.adobe.com

Canalicular gel Lacrifill (Nordic Pharma) receives CE Mark

Hattie Hayes
April 7th 2025
Article

Nordic Pharma plans to announce commercialisation details in the near future for the dry eye disease treatment

© 2025 MJH Life Sciences

All rights reserved.